• Revenue up 3.8% to $84.1M
• Normalised EBITDA of $5.0M
• Disruptive Technologies segment revenue up 40.2%

Trajan Group Holdings Ltd, a global developer and manufacturer of analytical and life sciences products and devices, reported its financial results for the half-year ended 31 December 2025. The Group's revenue increased by 3.8% to $84.1M, with the Components and Consumables segment growing 6.1% to $51.9M and the Disruptive Technologies segment increasing 40.2% to $3.1M. Normalised EBITDA for the period was $5.0M. The Capital Equipment segment experienced a 2.7% revenue decline due to purchasing caution in some sectors, but saw a recovery in the second quarter, especially in Pharma R&D demand. The Group continued to invest in research and development, spending $3.4M. Operating Net Loss After Tax plus Amortisation (Operating NPATA) was $0.8M, down $0.2M from the prior corresponding period. The Group's net assets stood at $103.1M as of 31 December 2025, with net debt increasing to $32.2M. No dividend was declared or proposed for the half-year.

The Group expects to deliver full-year FY26 revenue growth of 5-7% and normalised EBITDA margin of 8-10% compared to FY25.

Trajan remains focused on driving growth in its Components and Consumables and Disruptive Technologies segments, while optimizing margins in its Capital Equipment business. The Group will continue to invest in research and development to expand its product portfolio and strengthen its global footprint.